1-(3,4-dihydro-2H-chromen-2-yl)-2-[[2-(3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol | 125591-32-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 1-(3,4-dihydro-2H-chromen-2-yl)-2-[[2-(3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol
• CAS: 125591-32-4
• 化学式: C₂₂H₂₇NO₄
• 分子量: 369.5
• InChiKey: QSCYKSXNGYFRFZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  71
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(3,4-dihydro-2H-chromen-2-yl)-2-[[2-(3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol 、 氢溴酸 在 异丙醇 作用下， 以 异丙醇 为溶剂， 以yielding 0.8 parts of (A+A+)-α,α'-[iminobis(methylene)]bis[3,4-dihydro-2H-1-benzopyran-2-methanol]hydrobromide的产率得到alpha,alpha'-[iminobis(methylene)]bis[3,4-dihydro-2H-1-benzopyran-2-methanol]hydrobromide
  参考文献：
  名称：

  Derivatives of 2,2'-iminobisethanol

  摘要：

  2,2'-亚胺基双乙醇的衍生物具有在冠状血管系统的治疗和/或预防中有用的特性。

  公开号：

  US04654362A1
• 作为产物：
  描述：

  alpha,alpha'-[[(phenylmethyl)imino]bis(methylene)]bis[3,4-dihydro-2H-1-benzopyran-2-methanol] 、 氢气 在 钯 sodium hydroxide 、 水 作用下， 以 甲醇 为溶剂， 以yielding 1.2 parts (19%) of (A+A+)-α,α'-[iminobis(methylene)]bis[3,4-dihydro-2H-1-benzopyran-2-methanol]的产率得到1-(3,4-dihydro-2H-chromen-2-yl)-2-[[2-(3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol
  参考文献：
  名称：

  Derivatives of 2,2'-iminobisethanol

  摘要：

  2,2'-亚胺基双乙醇的衍生物具有在冠状血管系统的治疗和/或预防中有用的特性。

  公开号：

  US04654362A1

文献信息

• Hydroxylated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014733A1

  公开（公告）日：2007-01-18

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化奈必洛尔代谢物在急性给药后以浓度依赖性方式增加人内皮细胞制剂的一氧化氮释放。此外，羟基化奈必洛尔代谢物，包括但不限于4-羟基-6,6'-二氟代-、4-羟基-5-苯酚-6,6'-二氟代-和4-羟基-8-苯并-6,6'-二氟代-，在慢性给药后能够增加人内皮细胞的一氧化氮释放能力。本发明提供了羟基化奈必洛尔代谢物和包含奈必洛尔和/或至少一种羟基化奈必洛尔代谢物和/或至少一种用于治疗心血管疾病的附加化合物的组合物，以及可药用的盐。此外，本发明还提供了通过给药至少一种能够释放治疗有效量的一氧化氮到受血管疾病影响的靶向部位的羟基化奈必洛尔代谢物来治疗和/或预防血管疾病的方法。本发明还涉及通过给药至少一种羟基化奈必洛尔代谢物来治疗和/或预防偏头痛。本发明还可以与治疗代谢综合征障碍的其他治疗联合使用，或作为单一治疗。
• METHOD FOR PREPARING NEBIVOLOL
  申请人：Derrien Yvon

  公开号：US20110237808A1

  公开（公告）日：2011-09-29

  The present invention relates to a process for the preparation of nebivolol and, more particularly, to an improved process of synthesizing an alpha-haloketone of formula a key intermediate in the preparation of nebivolol.

  本发明涉及一种制备尼比洛尔的方法，更具体地说，涉及一种改进的合成α-卤代酮的方法，该酮是制备尼比洛尔的关键中间体。
• PROCESS FOR PREPARING NEBIVOLOL
  申请人：Volpicelli Raffaella

  公开号：US20100056813A1

  公开（公告）日：2010-03-04

  The present invention relates to a process for preparing nebivolol and, more particularly, to a process for preparing d-nebivolol and its enantiomer l-nebivolol or acid addition salts thereof starting from commercially available or easily obtainable 2,2-dimethyl-1,3 dioxolane-4-carbaldehyde and a vinyl Grignard reagent.

  本发明涉及一种制备尼倍洛尔的方法，更具体地说，涉及一种从商业上可获得或易于获得的2,2-二甲基-1,3-二氧兰-4-甲醛和乙烯基格氏试剂出发制备d-尼倍洛尔及其对映体l-尼倍洛尔或其酸加成盐的方法。
• The Process for Preparing Nebivolol
  申请人：Volpicelli Raffaella

  公开号：US20100069652A1

  公开（公告）日：2010-03-18

  The present invention relates to a process for the preparation of Nebivolol and, more particularly, to an improved method of synthesizing 6-fluoro chroman epoxides of formula (I) key intermediates in preparing nebivolol.

  本发明涉及一种制备奈必洛的方法，更具体地说，涉及一种合成式(I)的6-氟色酮环氧化物的改进方法，该化合物是制备奈必洛的关键中间体。
• HYDROXYLATED NEBIVOLOL METABOLITES
  申请人：O'Donnell John P.

  公开号：US20110065783A1

  公开（公告）日：2011-03-17

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化的内比洛尔代谢物在急性给药后以浓度依赖的方式增加人类内皮细胞制备的一氧化氮释放。此外，羟基化的内比洛尔代谢物，包括但不限于4-羟基-6,6′-二氟-、4-羟基-5-酚-6,6′-二氟-和4-羟基-8-苯基-6,6′-二氟-，具有在慢性给药后增加人类内皮细胞释放一氧化氮能力的能力。本发明提供了羟基化的内比洛尔代谢物和包含内比洛尔和/或至少一种内比洛尔羟基化代谢物和/或至少一种用于治疗心血管疾病的其他化合物或其药学上可接受的盐的组合物。此外，本发明提供了通过给靶向受影响的血管疾病的部位至少给予一种能够释放治疗有效量一氧化氮的内比洛尔羟基化代谢物的方法来治疗和/或预防血管疾病的方法。此外，本发明还涉及通过至少给予一种内比洛尔羟基化代谢物来治疗和/或预防偏头痛。此发明还可与代谢综合征疾病的单个治疗或联合治疗一起使用。